COMPANY
Enalare Therapeutics Inc.
Our lead drug candidate, ENA-001, is a patent-protected new chemical entity (NCE) beginning additional clinical trials during the fourth quarter of 2021. From company website Source · Oct 13, 2026
Timeline
- Trial start Phase 2: ENA-001 for Post Operative Respiratory Depression (PORD) source ↗
- Trial start Phase 1: ENA-001 for Opioid Induced Respiratory Depression source ↗
- Grant Government grant — SBIR: $2.5M (annual award, as published), announced Jan 3, 2025. Agency: NIH/NIDA. Source: government award database. source ↗
Upcoming milestones
- Jun 15, 2027 (ESTIMATED) · Phase 2 · ENA-001 for Post Operative Respiratory Depression (PORD) · NCT06137638
Funding
- Government grant — SBIR: $2.5M (annual award, as published), announced Jan 3, 2025. Agency: NIH/NIDA. Source: government award database. source ↗
Clinical trials (lead sponsor) 2
| Record | Title | Phase | Status | Start | Primary completion |
|---|---|---|---|---|---|
| NCT06967259 | ENA-001 for Opioid Induced Respiratory Depression | Phase 1 | Completed | May 14, 2025 | Aug 12, 2026 (actual) |
| NCT06137638 | ENA-001 for Post Operative Respiratory Depression (PORD) | Phase 2 | Not yet recruiting | Dec 15, 2026 | Jun 15, 2027 (estimated) |